Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Listen to expert discussions and interviews in pharma and biopharma.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
March 7, 2014
By: Michael A.
Director, Fairmount Partners
After 14 years of working with founding editor Gil Roth, I’m retiring this Financial Analysis column. Thanks for your support, Gil! My hat’s off to those who write any regular column for any type of publication; it’s not always easy to come up with a few hundred words that make a compelling point. In this last column, I want to offer some parting thoughts about making financial decisions. Unintended Consequences I’ve written about this topic more than once. But the idea is worth repeating — please go out of your way to consider as many potential consequences as possible before making any financial decision. It’s easy to use computer models to show the likely effects of raising or lowering prices, expanding or contracting capacity, changing a compensation formula, or adjusting a fringe benefit package. Studies from the Congressional Budget Office (CBO) are notorious for overstating the gain in revenue from a federal tax increase, because they do not consider the dynamic effect of potential behavioral changes made by those subject to that increase. Even minor financial modifications made at the margin can lead to unforeseen changes that will lessen the impact of the new policy. Analysis Paralysis Don’t fail to make critical financial decisions while you engage in superfluous financial analysis. Model the decision, consider the unintended consequences, and examine the alternate “what if” scenarios. But resist the temptation to conduct multiple, multi-dimensional, and time-consuming studies of every potential action. Competitors will not stand still while you model out every potential outcome and seek financial clarity about a project’s return to the fourth decimal point. Also, market conditions can change rapidly; your extensive (over)analysis might be useful in a graduate school business class, but might not be particularly relevant if the conditions that exist when you’re ready to make the decision have changed from those that prevailed when you began analyzing the project. I had a professor in college who always urged us to “pay your money and make your choice” and do so after only taking an “appropriate” amount of time for analysis. Understand the Impact of Different Types of Incorrect Decisions I had another professor in college who wanted to us to ask the question, “How would I rather be wrong? Would I rather make an error of commission or one of omission?” Many people I meet think it’s ridiculous to assume you might make an incorrect decision. But I’ve found it very useful to examine and evaluate the potential negative impact of various types of decisions. For instance, would I rather spend the money to fix an old but functional piece of expensive equipment, and take a chance that something else might go wrong with it in the near future? Or spend much more money buying a new piece of equipment, suffer the downtime involved in replacing it, and miss the chance to do something else with those funds?
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !